

# Rabbit anti-Human IgG Fc Secondary Antibody, FITC

Product Details	
Size	1.5 mg
Species Reactivity	Human
Host/Isotype	Rabbit / IgG
Class	Polyclonal
Type	Secondary Antibody
Conjugate	FITC
Excitation/Emission Max	498/517 nm
Form	Lyophilized
Concentration	1.5 mg/mL
Purification	Affinity chromatography
Storage buffer	PBS, pH 7.6, with 15mg/mL BSA
Contains	0.05% sodium azide
Storage conditions	4° C, store in dark
RRID	AB_228408

Applications	Tested Dilution	Publications
Immunohistochemistry (IHC)	1:50 - 1:200	-
Immunocytochemistry (ICC/IF)	1:50 - 1:200	-
Flow Cytometry (Flow)	1:50 - 1:200	0 Publication
Immunoprecipitation (IP)	1:50 - 1:200	-

## Product Specific Information

Concentration may vary slightly from lot-to-lot, see lot-specific datasheet for exact concentration.

This antibody has been successfully used in Western blot, IF, ICC, IHC, IP and FACS applications.

**Antibody Specificity:** This antibody reacts with the heavy chains of human IgG, but not with the light chains on most human immunoglobulins. No antibody was detected against human IgM, IgA, or non-immunoglobulin serum proteins. However, this antibody may cross-react with immunoglobulins from other species.

**Fluorophore:** Fluorescein-5-isothiocyanate (FITC-isomer 1)

**Amax** = 492 nm; **Emax** = 520 nm

**Fluorophore/Protein:** 7.5 µg/mg; 2.8 moles FITC per mole IgG


**Restoration and Storage:** Store product at 4°C until opened. Restore with 1.1 mL distilled water (1.5 mg/mL after restoration). Centrifuge product if it is not completely clear after standing for 1-2 hours at room temperature. To judge clarity, draw product into a pasteur pipette. Product may be stored for several weeks at 4°C as an undiluted liquid. After dilution, do not use for more than one day.

To extend the shelf-life of this product, add an equal volume of glycerol to make a final concentration of approximately 50%

glycerol and store at -20°C.

Country of Origin: USA

Product Images For Rabbit anti-Human IgG Fc Secondary Antibody, FITC



Human IgG Fc Secondary Antibody (31535) in Flow

CAR architecture, expression on engineered T cells, and binding of CAR-T cells to target cells. (A) The architecture of three different CAR constructs used in this study. In the original construct (tMUC1-CAR), scFv of TAB004 Ab is linked to CD28 transmembrane (TM) domain followed by CD28 and CD3 intracellular domains in a retroviral plasmid. CD8a leader sequence was used as signal peptide for cell membrane expression of the CAR. In the CTL-CAR construct, scFv of TAB was removed. In the CAR-mKate construct, mKate2 gene was fused to the C-terminus of CAR flanking with a GA linker. (B) CTL-CAR and tMUC1-CAR expression measured by flow cytometry using FITC-conjugated anti-myc tag Ab, in CD4+ and CD8+ primary T cells on day 12 after infection. On average, 42% of T cells expressed tMUC1-CAR. (C) Bright field (top left) and fluorescent image (top right) of live T cells expressing CAR-mKate plated in 35 mm poly-D-lysine coated MatTek dish and imaged by DeltaVision workstation (Applied Precision, GE), projection image of a T cell expressing CAR-mKate (bottom left), and one Z image of the CAR-mKate T cell (bottom right) illustrating the ring-like structure around the cells formed by CAR-mKate expression, which indicates even distribution of CAR molecules on the T cell membrane. (D) Light and fluorescent image of CAR-mKate T cells binding to MUC1 expressing cancer cell (HPAFII). HPAFII cells were incubated with CAR-mKate T cells ... Image collected and cropped by CiteAb from the following publication (<https://www.mdpi.com/2073-4409/8/9/1070>), licensed under a CC BY license.

1 Reference

Zearalenone Removal from Corn Oil by an Enzymatic Strategy. Toxins (Basel) (2020)

Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma. Cells (2019)

Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal Adenocarcinoma bioRxiv (2019)

A postsynaptic PI3K-cII dependent signaling controller for presynaptic homeostatic plasticity. Elife (2018)

Efficient degradation of sulfamethoxazole by the Fe(II)/HSO5- process enhanced by hydroxylamine: Efficiency and mechanism. J Hazard Mater (2017)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.